La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Alcon Résultats passés

Passé contrôle des critères 5/6

Alcon a connu une croissance annuelle moyenne de ses bénéfices de 64.5%, tandis que le secteur Medical Equipment a vu ses bénéfices augmenter de en hausse à 10.6% par an. Les revenus ont augmenté de en hausse à un taux moyen de 6.7% par an. Le rendement des capitaux propres de Alcon est 5% et ses marges nettes sont de 11%.

Informations clés

64.5%

Taux de croissance des bénéfices

64.5%

Taux de croissance du BPA

Medical Equipment Croissance de l'industrie	11.1%
Taux de croissance des recettes	6.7%
Rendement des fonds propres	5.0%
Marge nette	11.0%
Prochaine mise à jour des résultats	21 Aug 2024

Mises à jour récentes des performances passées

Recent updates

Results: Alcon Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Mar 01

Alcon (VTX:ALC) Has A Pretty Healthy Balance Sheet

Feb 15

Alcon Inc.'s (VTX:ALC) Business Is Yet to Catch Up With Its Share Price

Dec 22

Returns On Capital Are Showing Encouraging Signs At Alcon (VTX:ALC)

Dec 04

Calculating The Fair Value Of Alcon Inc. (VTX:ALC)

Nov 08

Alcon (VTX:ALC) Has A Pretty Healthy Balance Sheet

Oct 18

Alcon (VTX:ALC) Might Have The Makings Of A Multi-Bagger

Aug 25

A Look At The Fair Value Of Alcon Inc. (VTX:ALC)

Aug 10

Alcon (VTX:ALC) Has A Pretty Healthy Balance Sheet

Jul 05

Investors Will Want Alcon's (VTX:ALC) Growth In ROCE To Persist

May 12

Does Alcon (VTX:ALC) Have A Healthy Balance Sheet?

Apr 03

Here's Why Alcon (VTX:ALC) Has Caught The Eye Of Investors

Feb 03

Returns Are Gaining Momentum At Alcon (VTX:ALC)

Jan 19

Alcon (VTX:ALC) Has A Pretty Healthy Balance Sheet

Dec 18

Do Alcon's (VTX:ALC) Earnings Warrant Your Attention?

Nov 02

Alcon's (VTX:ALC) Returns On Capital Are Heading Higher

Sep 30

We Think Alcon (VTX:ALC) Can Stay On Top Of Its Debt

Sep 11

With Alcon Inc. (VTX:ALC) It Looks Like You'll Get What You Pay For

Aug 26

These 4 Measures Indicate That Alcon (VTX:ALC) Is Using Debt Reasonably Well

Jun 10

Alcon (VTX:ALC) Is Experiencing Growth In Returns On Capital

May 20

There's Been No Shortage Of Growth Recently For Alcon's (VTX:ALC) Returns On Capital

Feb 13

Does Alcon (VTX:ALC) Have A Healthy Balance Sheet?

Dec 28

We Like These Underlying Return On Capital Trends At Alcon (VTX:ALC)

Oct 26

Does Alcon (VTX:ALC) Have A Healthy Balance Sheet?

Sep 15

Alcon's (VTX:ALC) Robust Earnings Are Supported By Other Strong Factors

Aug 24

Ventilation des recettes et des dépenses

Comment Alcon gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.

Historique des gains et des recettes

SWX:ALC Recettes, dépenses et bénéfices (USD Millions )
Date	Recettes	Les revenus	Dépenses G+A	Dépenses de R&D
31 Mar 24	9,562	1,048	3,226	842
31 Dec 23	9,455	974	3,209	845
30 Sep 23	9,274	450	3,177	837
30 Jun 23	9,085	362	3,141	795
31 Mar 23	8,880	341	3,112	759
31 Dec 22	8,717	335	3,068	723
30 Sep 22	8,695	571	3,131	684
30 Jun 22	8,657	457	3,145	706
31 Mar 22	8,550	460	3,125	703
31 Dec 21	8,291	376	3,076	703
30 Sep 21	8,082	332	2,980	706
30 Jun 21	7,818	183	2,884	680
31 Mar 21	6,922	-390	2,690	665
31 Dec 20	6,833	-531	2,694	675
30 Sep 20	6,806	-717	2,647	678
30 Jun 20	6,836	-636	2,662	702
31 Mar 20	7,525	-604	2,827	707
31 Dec 19	7,508	-656	2,802	690
30 Sep 19	7,386	-638	2,830	735
30 Jun 19	7,280	-779	2,827	688
31 Mar 19	7,177	-362	2,761	665
31 Dec 18	7,153	-227	2,799	653
30 Sep 18	7,123	175	2,725	527
31 Dec 17	6,792	256	2,596	545
31 Dec 16	6,596	-170	2,526	481
31 Dec 15	6,776	308	2,337	457

Des revenus de qualité: ALC a des bénéfices de haute qualité.

Augmentation de la marge bénéficiaire: Les marges bénéficiaires nettes actuelles de ALC (11%) sont supérieures à celles de l'année dernière (3.8%).

Analyse des flux de trésorerie disponibles par rapport aux bénéfices

Analyse de la croissance passée des bénéfices

Tendance des revenus: ALC est devenue rentable au cours des 5 dernières années, augmentant ses bénéfices de 64.5% par an.

Accélération de la croissance: La croissance des bénéfices de ALC au cours de l'année écoulée ( 207.3% ) dépasse sa moyenne sur 5 ans ( 64.5% par an).

Bénéfices par rapport au secteur d'activité: La croissance des bénéfices ALC au cours de l'année écoulée ( 207.3% ) a dépassé celle du secteur Medical Equipment -2.4%.

Rendement des fonds propres

ROE élevé: Le retour sur capitaux propres de ALC ( 5% ) est considéré comme faible.

Alcon Résultats passés

Passé contrôle des critères 5/6

Informations clés

Mises à jour récentes des performances passées

First quarter 2024 earnings: EPS exceeds analyst expectations

Full year 2023 earnings: EPS exceeds analyst expectations

Third quarter 2023 earnings: EPS exceeds analyst expectations

Second quarter 2023 earnings released: EPS: US$0.34 (vs US$0.30 in 2Q 2022)

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: EPS misses analyst expectations

Recent updates

Alcon Inc. Announces Executive Changes, Effective September 1, 2024

Now 24% undervalued

Investor Optimism Abounds Alcon Inc. (VTX:ALC) But Growth Is Lacking

A Look At The Fair Value Of Alcon Inc. (VTX:ALC)

Alcon's Latest Equipment Breakthrough Technologies, Unity VCS and Unity CS, Receive U.S. FDA 510(k) Clearance

Should You Be Adding Alcon (VTX:ALC) To Your Watchlist Today?

Alcon's (VTX:ALC) Returns On Capital Are Heading Higher

These 4 Measures Indicate That Alcon (VTX:ALC) Is Using Debt Reasonably Well

First quarter 2024 earnings: EPS exceeds analyst expectations

Upcoming dividend of CHF0.24 per share

Alcon Inc. Approves Gross Dividend

Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and Its Hydrus Microstent for Microinvasive Glaucoma Surgery

Dividend of CHF0.24 announced

Alcon Inc.'s (VTX:ALC) Shareholders Might Be Looking For Exit

Alcon Announces Management Changes

Here's Why Alcon (VTX:ALC) Has Caught The Eye Of Investors

Alcon Inc. Launches Clareon Presbyopia Correcting IOLs in India

President of North America notifies of intention to sell stock

Results: Alcon Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Alcon Inc. Proposes Dividend for the Year 2023

Full year 2023 earnings: EPS exceeds analyst expectations

Alcon (VTX:ALC) Has A Pretty Healthy Balance Sheet

Alcon Announces Positive Topline Results from Phase 3 Comet Trials of AR-15512, A Novel Topical Drug Candidate for Dry Eye

Alcon Inc.'s (VTX:ALC) Business Is Yet to Catch Up With Its Share Price

Returns On Capital Are Showing Encouraging Signs At Alcon (VTX:ALC)

Alcon Inc., Annual General Meeting, May 08, 2024

Alcon Inc. Revises Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations

Calculating The Fair Value Of Alcon Inc. (VTX:ALC)

Alcon Inc. Showcases Cloud-Based Planning and World-Class Digital Technologies During AAO 2023

Alcon (VTX:ALC) Has A Pretty Healthy Balance Sheet

Alcon Launches Total30 Multifocal Contact Lenses for Patients with Presbyopia

Alcon (VTX:ALC) Might Have The Makings Of A Multi-Bagger

Alcon Inc. Raises Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: EPS: US$0.34 (vs US$0.30 in 2Q 2022)

A Look At The Fair Value Of Alcon Inc. (VTX:ALC)

Alcon (VTX:ALC) Has A Pretty Healthy Balance Sheet

Head of Corporate Development notifies of intention to sell stock

Investors Will Want Alcon's (VTX:ALC) Growth In ROCE To Persist

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Alcon Inc. Provides Earnings Guidance for the Year 2023

Alcon Announces Results from a New Study Presented at the American Society of Cataract and Refractive Surgery Annual Meeting

Alcon Inc. Approves Dividend

Upcoming dividend of CHF0.21 per share at 0.3% yield

Does Alcon (VTX:ALC) Have A Healthy Balance Sheet?

Full year 2022 earnings: EPS misses analyst expectations

Now 21% undervalued

Alcon Inc. Announces Settlement of Litigation Related to Femtosecond Laser Assisted Cataract Surgery Devices

Alcon Launches New Total Toric Lenses for Astigmatic Patients

Here's Why Alcon (VTX:ALC) Has Caught The Eye Of Investors

Returns Are Gaining Momentum At Alcon (VTX:ALC)

Alcon Inc., Annual General Meeting, May 05, 2023

Alcon Introduces a Premium, Reusable Toric Lens with Launch of TOTAL30 for Astigmatism

Alcon (VTX:ALC) Has A Pretty Healthy Balance Sheet

Now 20% undervalued

Alcon Inc. Updates Earnings Guidance for the Year 2022

Insufficient new directors

Alcon Inc. Revises Revenue Guidance for 2022

Do Alcon's (VTX:ALC) Earnings Warrant Your Attention?

Alcon Completes Availability of Clareon Portfolio with Clareon Toric During AAO 2022

Alcon's (VTX:ALC) Returns On Capital Are Heading Higher

We Think Alcon (VTX:ALC) Can Stay On Top Of Its Debt

With Alcon Inc. (VTX:ALC) It Looks Like You'll Get What You Pay For

Alcon Inc. (SWX:ALC) entered into a definitive merger agreement to acquire Aerie Pharmaceuticals, Inc. (NasdaqGM:AERI) for approximately $770 million.

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations

Alcon Inc. Revises Revenue Guidance for 2022

These 4 Measures Indicate That Alcon (VTX:ALC) Is Using Debt Reasonably Well

Alcon Inc. (SWX:ALC) acquired EYSUVIS® from Kala Pharmaceuticals, Inc. (NasdaqGS:KALA) for $60 million.